BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

489 related articles for article (PubMed ID: 16111461)

  • 21. Luteinizing hormone-releasing hormone analogues--the rationale for adjuvant use in premenopausal women with early breast cancer.
    Jonat W
    Br J Cancer; 1998 Sep; 78 Suppl 4(Suppl 4):5-8. PubMed ID: 9741781
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ovarian protection with goserelin during adjuvant chemotherapy for pre-menopausal women with early breast cancer (EBC).
    Urruticoechea A; Arnedos M; Walsh G; Dowsett M; Smith IE
    Breast Cancer Res Treat; 2008 Aug; 110(3):411-6. PubMed ID: 17851753
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer--Austrian Breast and Colorectal Cancer Study Group Trial 5.
    Jakesz R; Hausmaninger H; Kubista E; Gnant M; Menzel C; Bauernhofer T; Seifert M; Haider K; Mlineritsch B; Steindorfer P; Kwasny W; Fridrik M; Steger G; Wette V; Samonigg H;
    J Clin Oncol; 2002 Dec; 20(24):4621-7. PubMed ID: 12488405
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adjuvant endocrine treatment in premenopausal early breast cancer.
    Orlando L; Fedele P; Cinefra M; Sponziello F; Calvani N; Chetrì MC; Rizzo P; D'Amico M; Schiavone P; Portaluri M; Criscuolo M; Burlizzi S; Cinieri S
    Oncology; 2009; 77 Suppl 1():9-13. PubMed ID: 20130426
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of ovarian ablation in the management of breast cancer.
    Wirk B
    Breast J; 2005; 11(6):416-24. PubMed ID: 16297086
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ovarian ablation as adjuvant therapy for early-stage breast cancer.
    Pritchard KI
    Cancer Treat Res; 1998; 94():158-80. PubMed ID: 9587687
    [No Abstract]   [Full Text] [Related]  

  • 27. Paradigm shift in adjuvant treatment of receptor positive premenopausal breast cancer patients? Not yet!
    Samur M; Bozcuk HS
    J Clin Oncol; 2003 Jun; 21(12):2444; author reply 2445-7. PubMed ID: 12805349
    [No Abstract]   [Full Text] [Related]  

  • 28. Failure of ovarian ablation with goserelin in a pre-menopausal breast cancer patient resulting in pregnancy: a case report and review of the literature.
    Hill N; Madarnas Y
    Breast Cancer Res Treat; 2011 Aug; 129(1):265-8. PubMed ID: 21541703
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The use of GnRH analogues in early and advanced breast carcinomas].
    Ségura C; Avenin D; Gligorov J; Selle F; Estéso A; Beerblock K; Emile G; Do Huyen N; Lotz JP
    Gynecol Obstet Fertil; 2005 Nov; 33(11):914-9. PubMed ID: 16246613
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: a comparative endocrine study.
    Celio L; Martinetti A; Ferrari L; Buzzoni R; Mariani L; Miceli R; Seregni E; Procopio G; Cassata A; Bombardieri E; Bajetta E
    Anticancer Res; 1999; 19(3B):2261-8. PubMed ID: 10472341
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adjuvant endocrine therapy in premenopausal women with breast cancer.
    González Martín A; de la Cruz S; Márquez R
    Breast Cancer Res Treat; 2010 Sep; 123 Suppl 1():43-7. PubMed ID: 20711666
    [No Abstract]   [Full Text] [Related]  

  • 32. Combined ovarian ablation and aromatase inhibition as first-line therapy for hormone receptor-positive metastatic breast cancer in premenopausal women: report of three cases.
    El-Saghir NS; El-Hajj II; Makarem JA; Otrock ZK
    Anticancer Drugs; 2006 Sep; 17(8):999-1002. PubMed ID: 16940812
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [LH-RH analogue for the treatment in premenopausal, receptor-positive breast cancer].
    Sano M; Makino H
    Nihon Rinsho; 2000 Apr; 58 Suppl():328-33. PubMed ID: 11026014
    [No Abstract]   [Full Text] [Related]  

  • 34. Goserelin: a review of its use in the treatment of early breast cancer in premenopausal and perimenopausal women.
    Cheer SM; Plosker GL; Simpson D; Wagstaff AJ
    Drugs; 2005; 65(18):2639-55. PubMed ID: 16392882
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adjuvant therapy for breast cancer.
    Hennessy BT; Pusztai L
    Minerva Ginecol; 2005 Jun; 57(3):305-26. PubMed ID: 16166938
    [TBL] [Abstract][Full Text] [Related]  

  • 36. What is the role of ovarian ablation in the management of primary and metastatic breast cancer today?
    Prowell TM; Davidson NE
    Oncologist; 2004; 9(5):507-17. PubMed ID: 15477635
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [A case of premenopausal stage IV breast cancer responding to neoadjuvant endocrine therapy after chemotherapy with FEC].
    Konishi K; Hasegawa N; Kaneko H; Iimura Y; Shoji Y; Kawabata M
    Gan To Kagaku Ryoho; 2010 Jan; 37(1):111-3. PubMed ID: 20087042
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [A case of premenopausal metastatic breast cancer treated with goserelin plus aromatase inhibitor as second-line endocrine therapy].
    Baba S; Oji Y; Teramoto M; Kawabata K; Saito A
    Gan To Kagaku Ryoho; 2009 Nov; 36(11):1905-6. PubMed ID: 19920398
    [TBL] [Abstract][Full Text] [Related]  

  • 39. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
    Goel S; Sharma R; Hamilton A; Beith J
    Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD004562. PubMed ID: 19821328
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study.
    Gerber B; von Minckwitz G; Stehle H; Reimer T; Felberbaum R; Maass N; Fischer D; Sommer HL; Conrad B; Ortmann O; Fehm T; Rezai M; Mehta K; Loibl S;
    J Clin Oncol; 2011 Jun; 29(17):2334-41. PubMed ID: 21537042
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.